[go: up one dir, main page]

IL154229A0 - Chemokine receptor binding heterocyclic compounds - Google Patents

Chemokine receptor binding heterocyclic compounds

Info

Publication number
IL154229A0
IL154229A0 IL15422901A IL15422901A IL154229A0 IL 154229 A0 IL154229 A0 IL 154229A0 IL 15422901 A IL15422901 A IL 15422901A IL 15422901 A IL15422901 A IL 15422901A IL 154229 A0 IL154229 A0 IL 154229A0
Authority
IL
Israel
Prior art keywords
chemokine receptor
receptor binding
heterocyclic compounds
binding heterocyclic
compounds
Prior art date
Application number
IL15422901A
Other languages
English (en)
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of IL154229A0 publication Critical patent/IL154229A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15422901A 2000-09-15 2001-09-17 Chemokine receptor binding heterocyclic compounds IL154229A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23289100P 2000-09-15 2000-09-15
US23308700P 2000-09-15 2000-09-15
US23481600P 2000-09-22 2000-09-22
US23451000P 2000-09-22 2000-09-22
PCT/US2001/029590 WO2002034745A1 (fr) 2000-09-15 2001-09-17 Composes heterocycliques se liant au recepteur de la chimiokine

Publications (1)

Publication Number Publication Date
IL154229A0 true IL154229A0 (en) 2003-07-31

Family

ID=27499667

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15422901A IL154229A0 (en) 2000-09-15 2001-09-17 Chemokine receptor binding heterocyclic compounds

Country Status (16)

Country Link
US (3) US6734191B2 (fr)
EP (2) EP1752455B1 (fr)
KR (1) KR20030034184A (fr)
AT (2) ATE335733T1 (fr)
AU (1) AU2001294628B2 (fr)
BR (1) BR0113932A (fr)
CA (1) CA2421796A1 (fr)
DE (2) DE60143457D1 (fr)
DK (1) DK1317451T3 (fr)
ES (1) ES2269465T3 (fr)
HU (1) HUP0302960A3 (fr)
IL (1) IL154229A0 (fr)
NO (1) NO20031161L (fr)
NZ (1) NZ524651A (fr)
PT (1) PT1317451E (fr)
WO (1) WO2002034745A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000276225B2 (en) * 1999-09-28 2008-07-10 Neurogen Corporation High affinity small molecule C5A receptor modulators
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
JP5260818B2 (ja) * 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
WO2002094264A1 (fr) 2001-05-23 2002-11-28 Tularik Inc. Antagonistes de ccr4
EP3632425A1 (fr) 2001-07-31 2020-04-08 Genzyme Global S.à.r.l. Procédés pour mobiliser des cellules souches/progénitrices
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
JP4556020B2 (ja) * 2001-12-21 2010-10-06 ジェンザイム・コーポレーション 高い有効性を有するケモカインレセプタ結合複素環式化合物
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
JP3714948B2 (ja) * 2002-09-11 2005-11-09 呉羽化学工業株式会社 アミン化合物及びその用途
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
CA2520259A1 (fr) 2003-04-11 2004-10-28 Anormed Inc. Composes de liaison aux recepteurs de chimiokine cxcr4
JP4778420B2 (ja) 2003-04-22 2011-09-21 アノーメッド インコーポレイティド 増強された有効性を有するケモカインレセプタ結合複素環式化合物
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
RU2228930C1 (ru) * 2003-05-20 2004-05-20 ООО "Исследовательский институт химического разнообразия" Замещенные 3-пиридилметиламины и фокусированная библиотека
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
CA2548393A1 (fr) 2003-12-11 2005-06-30 Anormed Inc. Composes de liaison aux recepteurs de la chemokine
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
RU2006136381A (ru) * 2004-03-15 2008-04-27 Анормед, Инк. (Ca) Способ получения антагониста cxcr4
EP1778231A4 (fr) * 2004-08-02 2009-06-03 Smithkline Beecham Corp Composes chimiques
EP1796716A4 (fr) * 2004-08-13 2010-09-08 Anormed Inc Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
TW200619217A (en) * 2004-08-16 2006-06-16 Smithkline Beecham Corp Chemical compounds
EP1799671A4 (fr) * 2004-09-02 2009-06-10 Smithkline Beecham Corp Composes chimiques
US20080171740A1 (en) * 2004-09-24 2008-07-17 Smithkline Beecham Corporation Chemical Compounds
CA2612325A1 (fr) 2005-06-15 2006-12-28 Anormed Inc. Composes de liaison au recepteur de la chimiokine
CN101365336B (zh) 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
TW200738711A (en) * 2006-01-25 2007-10-16 Smithkline Beecham Corp Chemical compounds
AR063470A1 (es) * 2006-08-02 2009-01-28 Genzyme Corp Terapia combinada
US20100178271A1 (en) * 2006-08-07 2010-07-15 Genzyme Corporation Combination Therapy
US20090048295A1 (en) * 2007-08-13 2009-02-19 Joseph Kent Barbay Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
WO2009073620A2 (fr) * 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
CN114716426A (zh) 2013-08-21 2022-07-08 詹森生物制药有限公司 抗病毒化合物
US9556146B2 (en) 2014-10-24 2017-01-31 Biotherapeutics, Inc. Lanthionine synthetase C-like 2-based therapeutics
CA3026154A1 (fr) 2015-06-03 2016-12-08 The University Of Queensland Agents mobilisateurs et leurs utilisations
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
CA3008279A1 (fr) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methodes de traitement du cancer
WO2017112894A1 (fr) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Méthodes pour le traitement d'une maladie immunodéficiente
EP3440112A4 (fr) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017216368A1 (fr) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Composés utiles pour faire baisser le taux d'interféron
EP3471727B1 (fr) 2016-06-21 2020-12-09 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021127472A1 (fr) 2019-12-20 2021-06-24 Landos Biopharma, Inc. Ligands de la protéine 2 de type lanthionine c, cellules préparées avec ceux-ci, et thérapies les utilisant
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
CA2319781A1 (fr) * 1998-02-02 1999-08-05 Liping Wang Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine
JPH11269146A (ja) 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
WO2000042852A1 (fr) * 1999-01-25 2000-07-27 Smithkline Beecham Corporation Composes et procedes
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6362201B1 (en) * 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
US6864265B2 (en) 2000-09-15 2005-03-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US10468384B2 (en) 2017-09-15 2019-11-05 STATS ChipPAC Pte. Ltd. Semiconductor device and method of forming embedded die substrate, and system-in-package modules with the same

Also Published As

Publication number Publication date
NO20031161D0 (no) 2003-03-13
DE60122175D1 (de) 2006-09-21
EP1752455A3 (fr) 2007-02-28
PT1317451E (pt) 2006-12-29
NZ524651A (en) 2005-08-26
DE60143457D1 (de) 2010-12-23
WO2002034745A1 (fr) 2002-05-02
US6734191B2 (en) 2004-05-11
EP1317451A1 (fr) 2003-06-11
US20040171638A1 (en) 2004-09-02
NO20031161L (no) 2003-03-13
EP1317451B1 (fr) 2006-08-09
ATE487710T1 (de) 2010-11-15
US7807694B2 (en) 2010-10-05
DE60122175T2 (de) 2007-07-05
EP1752455B1 (fr) 2010-11-10
CA2421796A1 (fr) 2002-05-02
ATE335733T1 (de) 2006-09-15
HUP0302960A3 (en) 2007-03-28
BR0113932A (pt) 2003-06-24
HK1059257A1 (en) 2004-06-25
AU2001294628B2 (en) 2007-06-07
DK1317451T3 (da) 2006-12-18
WO2002034745A8 (fr) 2003-09-18
US20030028022A1 (en) 2003-02-06
HUP0302960A2 (hu) 2003-12-29
US7091217B2 (en) 2006-08-15
US20060252795A1 (en) 2006-11-09
EP1752455A2 (fr) 2007-02-14
ES2269465T3 (es) 2007-04-01
KR20030034184A (ko) 2003-05-01

Similar Documents

Publication Publication Date Title
IL154229A0 (en) Chemokine receptor binding heterocyclic compounds
WO2002022600A3 (fr) Composes heterocycliques se liant avec les recepteurs de chimiokines
EE200100166A (et) 4-karboksüamino-2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
GR3036208T3 (en) Paroxetine methansulfonate
PL374229A1 (en) Indole or benzimidazole derivatives for modulating ik b kinase
ZA200001665B (en) Suspension device.
MXPA03008853A (es) Antagonistas de ccr5 utiles para el tratamiento del sida.
EG23269A (en) Record carrier and apparatus for scanning the record carrier.
EP1382113A4 (fr) Procedes et systemes d'amplification de puissance de signaux
DE60044320D1 (de) Empfangsgerät, Verfahren und Medien
GB2349001B (en) Maintaining input device identity
FI19992595L (fi) Tilaajalaitteen autentikointi
EP1248607A4 (fr) Antagonistes des recepteurs de l'urotensine ii
WO2002047456A3 (fr) Antagonistes des recepteurs de l'urotensine ii
WO2002057313A3 (fr) Composes de liaison et procedes d'identification de ces derniers
GB0101784D0 (en) Amplifier
EP1304140A4 (fr) Dispositif permettant d'abaisser et de porter a partir d'un emplacement sureleve
EG23359A (en) Record carrier and apparatus for scanning the record carrier.
DE60001002D1 (de) Kommunikationsanlage zum gemeinsamen empfang von informationen
GB2396263B (en) Amplifier device
ZA200301399B (en) Chemokine receptor binding heterocyclic compounds.
IT247392Y1 (it) Cuffia di protezione per giunto omocinetico.
AU9462801A (en) Chemokine receptor binding heterocyclic compounds
PL359523A1 (en) Chemokine receptor binding heterocyclic compounds
GB0016521D0 (en) Oakashield equine numnah/pad numnah